COMMUNIQUÉS West-GlobeNewswire

IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 34 - 2026
24/08/2026
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 17 au 21 août 2026 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la transaction Code [...]
Zealand Pharma – Notification of holding of treasury shares
24/08/2026
Company announcement – No. 42 / 2026 Zealand Pharma – Notification of holding of treasury shares Copenhagen, Denmark, August 24, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. [...]
Zealand Pharma - Transactions related to share buy-back program (week 34, 2026)
24/08/2026
Company announcement No. 41 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 34, 2026) Copenhagen, Denmark, August 24, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: [...]
Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan
24/08/2026
-- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan -- -- Commercial launch in Japan expected by end of 2026, pending final pricing determination -- BOSTON, Aug. 24, 2026 (GLOBE [...]
Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
24/08/2026
BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, [...]
Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions
24/08/2026
– Supplemental Biologics License Application (BLA) expected to be filed with the Food and Drug Administration (FDA) in November 2026 – – Supplemental BLA will be supported by results from three Phase 3 studies of ATEV, [...]
Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy
24/08/2026
Engagement advances clinical execution of IBC101, Liminatus’ CD19xCD22 bivalent CAR-T therapy for relapsed or refractory B-cell malignancies FULLERTON, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. ( [...]
Bionano to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
24/08/2026
SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that management will present and host 1x1 meetings at the H.C. Wainwright 28th Annual Global Investment Conference on [...]
ADARx Pharmaceuticals Receives FDA Fast Track Designation for Onvuzosiran for the Treatment of HAE
24/08/2026
SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today that it has received Fast [...]
AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer
24/08/2026
- Former Deputy Director of the FDA’s Office of Neuroscience - Dr. Lee has previously advised AEON through Clintrex Research LLC (Clintrex), an affiliate of BlueRidge Life Sciences, on the regulatory strategy for ABP- [...]
Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma
24/08/2026
Designation follows encouraging Phase 1 activity across multiple tumor types including 2L+ KRAS G12X pancreatic cancer Three potentially registration-enabling trials planned across pancreatic and lung cancers Additional [...]
InnoCare Reports 2026 Interim Results, Sustained Profitability and Key Milestones Achieved
24/08/2026
BEIJING, Aug. 24, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the interim results and business [...]
Seek Labs and NAMRU EURAFCENT Enter CRADA to Evaluate Field-Deployable Diagnostics for Infectious Diseases
24/08/2026
SALT LAKE CITY, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Seek Labs, a private TechBio company building programmable platforms to decode, program, and resolve diseases, today announced a Cooperative Research and Development [...]
R3 Vascular Expands Management Team with Two Senior Executives
24/08/2026
Appointments Support Accelerated Trial Enrollment, Market Development, Scalability, and Future Commercialization MOUNTAIN VIEW, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- R3 Vascular Inc., a medical device company [...]
Novo Nordisk A/S - share repurchase programme
24/08/2026
Bagsværd, Denmark, 24 August 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR [...]
Applied Biologics CEO and Former Marine F/A-18 Pilot Edward Britt Selected as Honorary Commander at Luke Air Force Base
24/08/2026
Former Marine Corps Captain selected to serve with leadership of the 56th Operational Medical Readiness Squadron SCOTTSDALE, Ariz., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Applied Biologics today announced that Edward Britt, [...]
The Dental Shaman Announces Major Expansion of Holistic Oral Health Education with New Book Collection, Wellness Innovation, and Global Awareness Initiative
24/08/2026
Leatherhead, Surrey, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Leatherhead, Surrey, United Kingdom – August 2026 — The Dental Shaman , founded by internationally recognized holistic dentist and educator Marc Mortiboys , today [...]
Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA
24/08/2026
– New PDUFA target action date of November 22, 2026 follows submission of additional Phase 3 HOPE-3 data and analyses supporting a refined proposed indication – SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Capricor [...]
GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026
24/08/2026
LA JOLLA, CA, Aug. 24, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company developing innovative therapies for inflammatory, fibrotic and autoimmune diseases, today [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum